Genfit S.A.

GENFIT: June 15, 2026 Combined Shareholders Meeting Results

2026-06-15 12:10:00

All resolutions recommended by the Board of Directors approved (quorum: 32.13 %) Lille (France); Cambridge, ( Massachusetts, United States); Zurich (Switzerland); June 15, 2026 - GENFIT (Euronext: GNFT),, a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the results of the Combined Shareholders Meeting which took place on June 15, 2026. The quorum on first convening amounted to 32.13 % and shareholders approved all of the resolutions, with the exception of resolution n°26 which was rejected in accordance with the recommendations of the Board of Directors.

GENFIT: June 15, 2026 Combined Shareholders Meeting Results

2026-06-15 12:10:00

All resolutions recommended by the Board of Directors approved (quorum: 32. 13 %) Lille (France); Cambridge, (Massachusetts, United States); Zurich (Switzerland); June 15, 2026 - GENFIT (Euronext: GNFT),, a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the results of the Combined Shareholders Meeting which took place on June 15, 2026.

GENFIT : Résultats de l’Assemblée Générale Mixte du 15 juin 2026

2026-06-15 12:10:00

L'ensemble des projets de résolutions recommandés par le Conseil d'Administration a été approuvé (quorum: 32,13 %) Lille (France), Cambridge (Massachusetts, États-Unis), Zurich (Suisse), le 15 juin 2026 - GENFIT (Euronext: GNFT), société biopharmaceutique engagée dans l'amélioration de la vie des patients atteints de maladies rares du foie pouvant engager le pronostic vital, annonce aujourd'hui les résultats de son Assemblée Générale Mixte convoquée le 15 juin 2026.

GENFIT: NASHnext®, Powered by GENFIT's Non-invasive Diagnostic Technology NIS4®, Launched via Labcorp's OnDemand Offering for Identification of At-Risk MASH

2026-06-08 12:00:00

Labcorp OnDemand enables convenient testing with the NASHnext® test, within a physician-directed care pathway to support identification of patients with at-risk MASH This model expands access and supports adoption of NASHnext®, enabling testing across a wider patient population Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), June 8, 2026 - GENFIT (Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced that access to Labcorp's NASHnext®, a diagnostic test to identify at-risk MASH (Metabolic dysfunction-Associated SteatoHepatitis), powered by GENFIT's proprietary non-invasive diagnostic technology NIS4®, is now available through Labcorp OnDemand. Labcorp's platform allows patients expanded access to certain diagnostic tests online, which a physician can approve and review without requiring an in-person doctor's visit.

GENFIT Annual General Meeting of June 15, 2026 - Shareholders' letter

2026-06-02 12:16:00

Dear Shareholders, We are pleased to send you, in the attached document, GENFIT's Shareholders' Letter published ahead of our Annual General Meeting to be held on June 15, 2026. This letter outlines the key elements currently shaping the Company's trajectory and presents the main milestones and perspectives related to its activities.

GENFIT Highlights Broad Scientific and Strategic Presence at EASL Congress 2026

2026-05-25 12:00:00

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 25, 2026 – GENFIT (Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today highlights its broad participation at EASL Congress 2026. This visibility reflects both its scientific momentum and its active involvement in the ACLF ecosystem, as well as its position at an inflection point in MASH, while also highlighting the continuous progress made in PBC, driven by its partner Ipsen.

GENFIT Reports First Quarter 2026 Financial Information and Provides a Corporate Update

2026-05-21 12:00:00

Lille (France); Cambridge, ( Massachusetts, United States); Zurich (Switzerland); May 21, 2026 - GENFIT (Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announces its cash position as of March 31, 2026 and revenues for the first three months of 20261 and provides a corporate update.

GENFIT : Assemblée Générale Mixte du 15 juin 2026 — modalités de mise à disposition des documents préparatoires

2026-05-11 13:00:00

Lille (France), Cambridge (Massachusetts, États-Unis), Zurich (Suisse), le 11 mai 2026 - GENFIT (Euronext: GNFT), société biopharmaceutique engagée dans l'amélioration de la vie des patients atteints de maladies rares du foie pouvant engager le pronostic vital, annonce aujourd'hui la publication dans l'édition du Bulletin des Annonces Légales Obligatoires (BALO) n° 56 du 11 mai 2026 de l'avis de réunion relatif à l'Assemblée Générale Mixte qui se déroulera le 15 juin 2026 à 10h00 (heure de Paris) dans les locaux de la Faculté de Pharmacie de Lille situés sur le Parc Eurasanté, 3 rue du Professeur Laguesse à Lille (59000), France.